Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma.

Summary

Using human asthma samples and mechanistic assays, the authors show that small extracellular vesicles from myeloid-derived regulatory cells deliver mitochondrial cargo to CD4+ T-helper cells, reprogramming their bioenergetics and effector profiles. Mitochondrial transfer emerges as a key determinant of T-helper cell function, suggesting a therapeutic axis to modulate type 2 inflammation.

Key Findings

• Small extracellular vesicles from myeloid-derived regulatory cells transfer mitochondria to CD4+ T-helper cells.
• Mitochondrial transfer reprograms T-helper bioenergetics and alters effector cytokine profiles in human asthma.
• Interfering with sEV-mediated organelle transfer modulates T-helper function, revealing a therapeutic axis.

Clinical Implications

Targeting sEV biogenesis, uptake, or mitochondrial cargo could modulate type 2 airway inflammation. EV-based or mitochondrial-targeted biomarkers may stratify patients and monitor response in severe asthma.

Limitations

• Primarily mechanistic/ex vivo data without interventional clinical trials
• Heterogeneity of EV sources and in vivo delivery not fully resolved

Future Directions

Define EV/mitochondrial cargo determinants of T-helper reprogramming in vivo, develop inhibitors or engineered EVs to modulate airway inflammation, and test biomarker-guided patient stratification in severe asthma trials.